Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Anyone on Twitter, might be worth sending them both a link to the RNS.
https://mobile.twitter.com/GDC_UK
https://mobile.twitter.com/MattHan****
Sets an admirable standard regarding 'turn around' - 6wks for results is very impressive.
And it won't go unnoticed.
It wouldn't surprise me if The General Dental Council are on board with this to be better able to manage and mitigate risk to dental surgeons and patients.
Yes, the pr side will be good, so it’s more a demonstrator research with monetary opportunities further down the line.
Good news that results are in approximately 6 weeks. Should have seen that in the RNS. Thanks SloppyGuiseppe
I would think the data extracted could be compared to different products to establish claims over products effectiveness, just imagine the marketing benefits of a hand wash that gives better protection than others, and a mouthwash that gives protection to dentists and patients durning a procedure, this information is worth a fortune on a number of levels. GB did say that assess to theses level 3 Labs was restricted and in high demand, this is very good news. I would not be surprised if the costs for this have been underwritten by a third party.
I might wait for the results before resuming my course of dental treatment. The findings could be very significant for dental practices.
“Results of the trial are expected in the next six weeks.”
Sounds like good news, but not sure how you monetise this research and the timescales involved. Anyone with knowledge on such things able to shed any light here.
Am a holder, so it a genuine query.
Integumen have done well to secure a Category 3 Laboratory, these must be in very high demand in these times.
Integumen PLC
("Integumen" or "Company")
Labskin partners with University of Aberdeen to test COVID19 anti-viral skin and dental products
Integumen today announces that its subsidiary, Labskin, will begin the immediate testing of anti-viral treatments on Labskin cloned human skin coated with SARS-CoV-2 virus to investigate the use of consumer and dental care products that have the potential to mitigate the risk of transmission of the disease.
Labskin has secured access to the SARS-CoV-2 virus Category 3 laboratory at the University of Aberdeen to assess the strain "SARS-CoV-2 England/2/2020" regarding its transmissibility impact to and from human skin without exposing human volunteers to dangerous clinical trial contamination risk:
· Study the transferability of viral particles from materials to skin
· Assess the ability of the virus to remain infective while on the skin surface
· Quantify the efficacy of mouthwash and dental care products
· Quantify the efficacy of soap washing and hand sanitisers
Gerard Brandon - CEO of Integumen plc, comments:
"COVID-19 has had such a dramatic impact on lives across world, it is important to find products that can help to mitigate the risk of infection, particularly, in professional settings. Labskin is in a unique position to aid the fight against COVID-19 and with the support of the University of Aberdeen, can facilitate testing of the COVID-19 virus on our cloned human skin. We will study the effects of a variety of products and ingredients in the university's secure Containment Level 3 laboratory environment without exposing human volunteers to dangerous and challenging clinical trial contamination risk. The more knowledge we have about SARS-CoV-2 - how it spreads, and more importantly, how to contain that spread - the better equipped to fight this virus we will be."
Skin, transmissibility and infection control trial
The trial involves testing anti-viral treatments on cloned human skin coated with SARS-CoV-2 enabling Labskin to investigate the use of washes and sanitizers and their effectiveness. It will determine:
1. If the virus is transmissible from different surfaces to airways via skin by measuring its viability when recovered from surface(s) to skin.
2. Sanitizers efficiency to kill the virus on skin.
3. The reduction of titer and/or virulence.
Results of the trial are expected in the next six weeks.
Dental practice infection risk
The trial will also investigate consumer and pre-procedural mouthwash dental care products that may mitigate the risk of transmission in dental practices using Labskin grown to mimic the oral and nasal cavities. Given the widespread transmission of SARS-CoV-2, and reports of its spread to health care providers, dental professionals are at high risk of infection and can become potential transmission carriers for the disease. These risk